Impact of Off-Label Low-Dose Rapamycin on Healthy Adults

Clinical studies are often limited to small numbers of participants and short durations.

by October 8, 2025

Comments Off on Impact of Off-Label Low-Dose Rapamycin on Healthy Adults

Research Overview:

  • Rapamycin has been found in some clinical trials to reduce inflammation at low doses.
  • Other clinical trials, including ones involving handgrip strength and walking speed, were less conclusive.
  • Many of these studies were found not to be sufficiently powered to yield statistically significant results.
  • Rapamycin continues to be studied in humans, including on brain function.

A team of scientists has reviewed the clinical data regarding low-dose rapamycin therapy in healthy adults. They concluded that, while there is plenty of preclinical data regarding the impact of rapamycin, there is limited human clinical evidence.

An Old Friend

Rapamycin is a well-known compound in the longevity field. It has anti-fungal, anti-tumorigenic, and immunomodulatory properties. Its name is included in the mechanistic target of rapamycin (mTOR), which is a regulator of cell growth, autophagy, and division, playing a crucial role in age-related diseases. The results of preclinical studies, including data from the Interventions Testing Program (ITP), suggest that rapamycin can be used to delay age-related diseases and extend mean and maximal lifespan in model systems.

Some individuals, encouraged by such preclinical data, use rapamycin off-label to achieve similar benefits; however, it is unclear if this promising data translates to humans. The authors of this paper reviewed the current evidence for using low-dose rapamycin and rapalog therapies in healthy human adults. They note that such evidence is minimal, with only a handful of trials that assessed different biomarkers.

They list several reasons for the scarcity of data:

  1. Human longevity studies are challenging and require a long time and substantial resources.
  2. Since rapamycin is a generic drug, there is limited financial incentive for private companies to invest in studying its different applications.

Nevertheless, a few studies have been performed, and the authors discuss their results.

The Dose Makes a Difference

The first study the reviewers discussed was conducted in 2014, investigating markers of immune function in 218 older adults. Those researchers used everolimus (RAD001), an mTOR complex 1 (mTORC1) rapalog, during an influenza vaccination trial [2]. The everolimus treatment resulted in a stronger and more youthful immune response, with some side effects such as benign mouth ulcers.

The same group conducted a phase 2 trial involving 264 healthy adults [3] using everolimus combined with an ATP-competitive kinase inhibitor (RTB101), claiming it reduced respiratory tract infections.

Further clinical trials at phases 2b and 3 demonstrated that 10 mg/day of RTB101 reduced respiratory tract infections compared to controls without significant side effects. This positive effect was not observed for different doses of RTB101 or the 10mg/day RTB101 + everolimus combination [4]. The analysis also showed improved immune functions.

The authors note the probability of a threshold where low mTOR inhibition obtained with low doses is beneficial for immune system function; however, higher levels may lead to immunosuppression.

They outline some caveats and limitations of these studies, noting:

  • An increase in respiratory tract infections in smokers.
  • Not all results were replicable between phases 2b and 3, with complications that limited statistical power.

The evidence is described as “compelling but not convincing at present.”

Not a Clear Answer

A separate study reported on individuals using rapamycin for longevity, documenting decreased incidences of COVID infection and long COVID. Participants self-reported improved well-being and physical stamina without side effects compared to non-users; however, caution is advised since this was not a blinded study [5].

An additional 2020 study observed the effects of 15-day everolimus use in 22 young men, leading to reduced levels of interleukins IL-2 and IL-10, one of which is associated with increased longevity. Some subjects experienced increased anxiety and heightened noradrenaline levels [6].

A study of 25 older adults (aged 70-95 years) using 1 mg/day sirolimus for 8 weeks showed no significant improvements in metabolic parameters, with minor changes in hematologic parameters that did not provide conclusive data. Although a reduction in body weight was noted, there was no change in handgrip strength or walking speed [7].

The review authors incorporated this study's data into a biological clock, PhenoAge. They observed that the rapamycin-treated group showed a change from 81.34 years down to 77.38 years, suggesting a reduced biological age. However, the limitations of the small sample size and missing biomarkers must be considered.

Theoretical studies utilizing Mendelian randomization suggest mTOR inhibition may promote longevity, but such associations were not universally established for all age-related diseases [8].

Many Unanswered Questions

When assessing the impacts of rapamycin on cardiovascular health, the researchers mentioned that while animal models suggest varying outcomes, human data remains scarce, limited mostly to biomarkers. Furthermore, the effects of low-dose rapamycin on cancer incidence or muscle protein synthesis are still unexplored.

No completed trials focus on cognitive functions; however, two ongoing Phase 2 trials aim to evaluate structural brain changes and markers of Alzheimer’s disease burden.

The review authors conclude that despite extensive preclinical evidence supporting sirolimus and other mTOR inhibitors as potential gero-therapeutics, human data is still insufficient to confirm if rapamycin can extend lifespan or delay age-related diseases. They emphasize the necessity for large clinical trials to explore these avenues. They highlight three critical areas for future investigation:

  1. Efficacy and clinical endpoints in healthy adults.
  2. Development of therapeutic dose-response curves.
  3. Interactions with other gerotherapeutics.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, and we rely on people like you. Every contribution, no matter how small, supports independent journalism and sustains our future.

Literature

  1. Hands, J. M., Lustgarten, M. S., Frame, L. A., & Rosen, B. (2025). What is the clinical evidence to support off-label rapamycin therapy in healthy adults?. Aging, 17(8), 2079–2088.
  2. Mannick, J. B., et al. (2014). mTOR inhibition improves immune function in the elderly. Science translational medicine, 6(268), 268ra179.
  3. Mannick, J. B., et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Science translational medicine, 10(449), eaaq1564.
  4. Mannick, J. B., et al. (2021). Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. The Lancet: Healthy Longevity, 2(5), e250–e262.
  5. Kaeberlein, T. L., et al. (2023). Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience, 45(5), 2757–2768.
  6. Hörbelt, T., et al. (2020). Dose-Dependent Acute Effects of Everolimus Administration on Immunological, Neuroendocrine and Psychological Parameters in Healthy Men. Clinical and Translational Science, 13(6), 1251–1259.
  7. Kraig, E., et al. (2018). A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Experimental Gerontology, 105, 53–69.
  8. Sobczyk, M. K., & Gaunt, T. R. (2023). Evaluating the life-extending potential and safety profile of rapamycin: a Mendelian Randomization study of the mTOR pathway. medRxiv. 10.02.23296427.
  9. Cai, H. Y., et al. (2023). Causal Association Between mTOR-Dependent Protein Levels and Alzheimer’s Disease: A Mendelian Randomization Study. Journal of Alzheimer’s Disease, 94(4), 1477–1485.
  10. Tan, C., Ai, J., & Zhu, Y. (2023). mTORC1-Dependent Protein and Parkinson’s Disease: A Mendelian Randomization Study. Brain Sciences, 13(4), 536.